Tags

Type your tag names separated by a space and hit enter

Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
Vaccine. 2004 Oct 22; 22(31-32):4215-27.V

Abstract

PURPOSE

Pertussis is a frequent cause of cough illness in adolescents. In Canada, until recently immunization against pertussis in public programmes has been restricted to children under the age of 7. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Ontario.

METHODS

We performed a cost effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 144,000 adolescents in Ontario from the age of 12 years over a 10-year-period from the Ontario Ministry of Health (MoH) and societal perspectives. The model was used to compare costs and benefits of a combined vaccination programme (CVP) including tetanus, diphtheria, and acellular pertussis (dTacp) administered at age 12, compared to current practice.

RESULTS

From the MoH perspective, booster vaccination of dacpT at 12 years via the CVP would produce a yearly additional expected cost of CAD $0.52 per adolescent in Ontario with an incremental cost-effectiveness ratio of CAD $168 per pertussis case avoided based on a 10-year-period. If outcomes are discounted at 3%, the incremental cost-effectiveness ratio rises to $188/discounted pertussis case avoided. From the societal perspective, the CVP would be cost saving CAD $858,106 at 10 years for the cohort. Over the 10-year-period, more than 4400 cases of pertussis would be prevented with approximately 50 hospital admissions averted.

CONCLUSIONS

This study suggests that administering a booster dose of dTacp at 12 years of age to replace diphtheria and tetanus vaccination at 14 years may reduce the economic burden of pertussis treatment in the long term at a reasonable cost.

Authors+Show Affiliations

PharmIdeas Research and Consulting Inc., Oakville, Ont., Canada. skedji@pharmideas.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15474711

Citation

Iskedjian, Michael, et al. "Economic Evaluation of an Extended Acellular Pertussis Vaccine Programme for Adolescents in Ontario, Canada." Vaccine, vol. 22, no. 31-32, 2004, pp. 4215-27.
Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine. 2004;22(31-32):4215-27.
Iskedjian, M., Walker, J. H., & Hemels, M. E. (2004). Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine, 22(31-32), 4215-27.
Iskedjian M, Walker JH, Hemels ME. Economic Evaluation of an Extended Acellular Pertussis Vaccine Programme for Adolescents in Ontario, Canada. Vaccine. 2004 Oct 22;22(31-32):4215-27. PubMed PMID: 15474711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. AU - Iskedjian,Michael, AU - Walker,John H, AU - Hemels,Michiel E H, PY - 2004/01/13/received PY - 2004/04/18/revised PY - 2004/04/28/accepted PY - 2004/10/12/pubmed PY - 2004/12/28/medline PY - 2004/10/12/entrez SP - 4215 EP - 27 JF - Vaccine JO - Vaccine VL - 22 IS - 31-32 N2 - PURPOSE: Pertussis is a frequent cause of cough illness in adolescents. In Canada, until recently immunization against pertussis in public programmes has been restricted to children under the age of 7. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Ontario. METHODS: We performed a cost effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 144,000 adolescents in Ontario from the age of 12 years over a 10-year-period from the Ontario Ministry of Health (MoH) and societal perspectives. The model was used to compare costs and benefits of a combined vaccination programme (CVP) including tetanus, diphtheria, and acellular pertussis (dTacp) administered at age 12, compared to current practice. RESULTS: From the MoH perspective, booster vaccination of dacpT at 12 years via the CVP would produce a yearly additional expected cost of CAD $0.52 per adolescent in Ontario with an incremental cost-effectiveness ratio of CAD $168 per pertussis case avoided based on a 10-year-period. If outcomes are discounted at 3%, the incremental cost-effectiveness ratio rises to $188/discounted pertussis case avoided. From the societal perspective, the CVP would be cost saving CAD $858,106 at 10 years for the cohort. Over the 10-year-period, more than 4400 cases of pertussis would be prevented with approximately 50 hospital admissions averted. CONCLUSIONS: This study suggests that administering a booster dose of dTacp at 12 years of age to replace diphtheria and tetanus vaccination at 14 years may reduce the economic burden of pertussis treatment in the long term at a reasonable cost. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15474711/Economic_evaluation_of_an_extended_acellular_pertussis_vaccine_programme_for_adolescents_in_Ontario_Canada_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(04)00369-X DB - PRIME DP - Unbound Medicine ER -